Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medical Cannabis for Nausea in Patients Receiving Moderately or Highly Emetogenic Chemotherapy
NCT07374939Phase 2Not yet recruiting
- Sponsor
- University of Rochester
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cannabis in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by University of Rochester. Primary endpoints: Average and Maximum Nausea Severity and Number of Emesis Episodes. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
cannabis
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT07374939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07374939.